A. Abdrakhmanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. Abdrakhmanova has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Dilyara Kaidarova
S.D. Asfendiyarov Kazakh National Medical University
5 shared publications - Калдыгуль Кабаковна Смагулова
Kazakh Institute of Oncology and Radiology
5 shared publications - A. Baizhigitov
JSC «Kazakh Institute of Oncology and Radiology
4 shared publications - Tatjana Goncharova
Kazakh Institute of Oncology and Radiology
4 shared publications - M. Dmitrenko
«Kazakh Institute of Oncology and Radiology» JSC
3 shared publications - N. Chichua
JSC «Kazakh Institute of Oncology and Radiology
3 shared publications
Latest Publications
- Open Access
- 3 December 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (4) , 81-87
Installation of preoperative and intraoperative fiducial markers for radiation therapy in mammary gland surgery (literature review)
Over 5,000 new cases of breast cancer are diagnosed in the Republic of Kazakhstan every year. More than 40 % of them are treated with organ-preserving surgery followed by radiation therapy to minimize the risk of local recurrence. Notably, over 70 % of breast cancer recurrences occur within the primary tumor bed. Radiation therapy aims to prevent recurrence after radical surgery, and precise targeting is crucial for its effectiveness. However, the lack of standardized methods for the exact localization of the tumor margin presents a significant challenge. Radiation oncologists must carefully determine the tumor bed when planning radiation therapy.Publications for analysis were searched in the PubMed and eLibrary databases using the relevant keywords.Titanium surgical clips are commonly used to localize the tumor cavity in mammary gland radical surgery. However, tissue movement and postoperative seroma formation can compromise the positioning of clips within the cavity, especially with abnormal fluid accumulation. Originally designed for hemostasis, these clips may create ambiguity when used to mark tumor bed margins. Various alternative methods for more precise delineation of tumor bed margins have advantages and limitations regarding practicality, patient comfort, and precision. Despite certain challenges in clinical application, gold markers remain the most efficient way of localizing primary tumors and resection margins.These findings highlight the urgent need for innovative approaches to marking the tumor cavity in mammary gland surgery to improve the precision of tissue localization for radiation therapy. Future advancements in this area should build on the advantages of gold markers and ensure accurate tumor localization.
- 3 December 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (4) , 81-87
Open AccessInstallation of preoperative and intraoperative fiducial markers for radiation therapy in mammary gland surgery (literature review)
Over 5,000 new cases of breast cancer are diagnosed in the Republic of Kazakhstan every year. More than 40 % of them are treated with organ-preserving surgery followed by radiation therapy to minimize the risk of local recurrence. Notably, over 70 % of breast cancer recurrences occur within the primary tumor bed. Radiation therapy aims to prevent recurrence after radical surgery, and precise targeting is crucial for its effectiveness. However, the lack of standardized methods for the exact localization of the tumor margin presents a significant challenge. Radiation oncologists must carefully determine the tumor bed when planning radiation therapy.Publications for analysis were searched in the PubMed and eLibrary databases using the relevant keywords.Titanium surgical clips are commonly used to localize the tumor cavity in mammary gland radical surgery. However, tissue movement and postoperative seroma formation can compromise the positioning of clips within the cavity, especially with abnormal fluid accumulation. Originally designed for hemostasis, these clips may create ambiguity when used to mark tumor bed margins. Various alternative methods for more precise delineation of tumor bed margins have advantages and limitations regarding practicality, patient comfort, and precision. Despite certain challenges in clinical application, gold markers remain the most efficient way of localizing primary tumors and resection margins.These findings highlight the urgent need for innovative approaches to marking the tumor cavity in mammary gland surgery to improve the precision of tissue localization for radiation therapy. Future advancements in this area should build on the advantages of gold markers and ensure accurate tumor localization.
- Open Access
- 26 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 32-47
The influence of polymorphism of genes associated with breast cancer on the effectiveness of drug antitumor therapy
Background. Increasing the survival rate of breast cancer patients is a problem all over the world and directly depends on the early detection of a malignant tumor. Genome-wide associative studies (GWAS) as a minimally invasive method may be used in determining risk of breast cancer or detection at an early stage. The increase in the number of patients with disseminated breast cancer in the Republic of Kazakhstan makes it necessary to search for molecular genetic markers of breast cancer for their use in the diagnosis and treatment of patients with this pathology.Aim. To retrospectively estimate the correlation of the effectiveness of drug antitumor therapy for breast cancer with gene polymorphism.Materials and methods. The study included the results of genotyping biomaterial samples on high-density DNA chips (venous blood of 1,277 Kazakh patients (in the third generation) with a verified diagnosis of breast cancer with locally advanced and disseminated breast cancer who received anticancer therapy), clinical data of patients, data on the clinical efficacy and toxicity of drug therapy. GWAS data (genotypes) associated with identified responses to chemotherapy drugs were compared with similar data recorded in international databases.Results. The family history study showed 16.52 % of women in the questionnaires had a family history of various types of ESR, and 86.25 % of them had a burden of breast cancer in women of the first degree of kinship. The average age of patients with breast cancer was 48.79 ± 11.44 years. According to the TNM classification, cancer in situ was detected in 4.78 % of patients, stage I of the disease was recorded in 15.27 %, stage II in 63.43 %, stage III in 12.60 %, stage IV in 3.92 % of patients. The vast majority of the patients (96.9 %) had a nodular form of breast cancer. The distribution of the patients by tumor phenotype: luminal type A was found in 20.4 % of patients, luminal type B in 38.3 %, luminal type B with HER2 overexpression in 14.3 %, HER2 positive form in 11.9 % of cases, 12.4 % of patients had an aggressive form – triple negative breast cancer. 18 main genotypes were identified in the Kazakh population as a result of the analysis of associations of the effectiveness of neoadjuvant chemotherapy (its individual components, according to chemotherapy regimens) and individual gene polymorphisms.Conclusion. An associative relationship between different types of gene polymorphism and the characteristics of response to various chemotherapeutic drugs used in the treatment of breast cancer has been confirmed. The obtained results formed the basis for the development of recommendations for making changes to the clinical practice of the Republic of Kazakhstan in order to use them in identifying a genetic predisposition to breast cancer and the effectiveness of drugs used in treatment.
- 26 July 2024
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (2) , 32-47
Open AccessThe influence of polymorphism of genes associated with breast cancer on the effectiveness of drug antitumor therapy
Background. Increasing the survival rate of breast cancer patients is a problem all over the world and directly depends on the early detection of a malignant tumor. Genome-wide associative studies (GWAS) as a minimally invasive method may be used in determining risk of breast cancer or detection at an early stage. The increase in the number of patients with disseminated breast cancer in the Republic of Kazakhstan makes it necessary to search for molecular genetic markers of breast cancer for their use in the diagnosis and treatment of patients with this pathology.Aim. To retrospectively estimate the correlation of the effectiveness of drug antitumor therapy for breast cancer with gene polymorphism.Materials and methods. The study included the results of genotyping biomaterial samples on high-density DNA chips (venous blood of 1,277 Kazakh patients (in the third generation) with a verified diagnosis of breast cancer with locally advanced and disseminated breast cancer who received anticancer therapy), clinical data of patients, data on the clinical efficacy and toxicity of drug therapy. GWAS data (genotypes) associated with identified responses to chemotherapy drugs were compared with similar data recorded in international databases.Results. The family history study showed 16.52 % of women in the questionnaires had a family history of various types of ESR, and 86.25 % of them had a burden of breast cancer in women of the first degree of kinship. The average age of patients with breast cancer was 48.79 ± 11.44 years. According to the TNM classification, cancer in situ was detected in 4.78 % of patients, stage I of the disease was recorded in 15.27 %, stage II in 63.43 %, stage III in 12.60 %, stage IV in 3.92 % of patients. The vast majority of the patients (96.9 %) had a nodular form of breast cancer. The distribution of the patients by tumor phenotype: luminal type A was found in 20.4 % of patients, luminal type B in 38.3 %, luminal type B with HER2 overexpression in 14.3 %, HER2 positive form in 11.9 % of cases, 12.4 % of patients had an aggressive form – triple negative breast cancer. 18 main genotypes were identified in the Kazakh population as a result of the analysis of associations of the effectiveness of neoadjuvant chemotherapy (its individual components, according to chemotherapy regimens) and individual gene polymorphisms.Conclusion. An associative relationship between different types of gene polymorphism and the characteristics of response to various chemotherapeutic drugs used in the treatment of breast cancer has been confirmed. The obtained results formed the basis for the development of recommendations for making changes to the clinical practice of the Republic of Kazakhstan in order to use them in identifying a genetic predisposition to breast cancer and the effectiveness of drugs used in treatment.
- 10 October 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 69 (3)
GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW
Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information. Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan. Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease.
- 10 October 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 69 (3)
GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW
Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information. Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan. Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease.
- 30 September 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 69 (3)
GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW
Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease
- 30 September 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 69 (3)
GENOME-WIDE ASSOCIATION STUDY IN BREAST CANCER: A LITERATURE REVIEW
Relevance: Breast cancer (BC) is one of the major health problems in the Republic of Kazakhstan. Genome-wide association studies (GWAS) are used to identify genetic factors contributing to breast cancer development in Kazakhstan and worldwide. The GWAS method consistently helps to find associations between certain single nucleotide polymorphisms (SNPs) in the genome and the development of pathological conditions, including breast cancer, by identifying more than 170 genomic sites. In addition to searching for loci associated with BC, these studies have expanded our understanding of BC heritability using SNPs located in regulatory areas and identifying DNA variants associated with drug metabolism for treatment personalization purposes. The study aimed to highlight the key concepts of modern methods in genetics based on GWAS. Methods: A literature search in PubMed, Scopus, GWAS Catalog, Cochrane Database of Systematic Reviews, etc., was performed to select and analyze relevant information Results: The article describes significant GWAS studies in the field of breast cancer, describes certain genes associated with the development of the disease, identifies shortcomings, and identifies further strategies for the development of GWAS in the Republic of Kazakhstan Conclusion: The results of this study have improved our understanding of the biological mechanisms that contribute to breast cancer risk and may ultimately lead to the development of new targeted therapies for the disease
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrate the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer of the right breast St III (T4NxM0), edematous-infiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3. Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years. * clinical case, male breast cancer (BC), luminal subtype B without Her2neu expression, mastectomy, therapeutic pathomorphism, radiation therapy, endocrine therapy.
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrate the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer of the right breast St III (T4NxM0), edematous-infiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3. Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years. * clinical case, male breast cancer (BC), luminal subtype B without Her2neu expression, mastectomy, therapeutic pathomorphism, radiation therapy, endocrine therapy.
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3 . Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3 . Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3 . Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.
- 30 December 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 66 (4)
MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower BC frequency in men limits the usefulness of screening. However, BC incidence in men is growing. This paper demonstrates the results of surgical treatment and typical changes in clinical and morphological manifestations of male breast cancer under chemotherapy and surgery. Methods: The article describes a clinical case of a male patient diagnosed with “Cancer in the right breast St III (T4NxM0), edematousinfiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”; the condition – after six neoadjuvant chemotherapy courses. Results: Ultrasonography of the mammary glands conducted after six preoperative courses of chemotherapy showed a hypoechoic formation, centralized, with fuzzy, uneven contours, 52.5×48.2×46.1 mm in size, V=60.98 cm3 . Compared to March 2022 (the presence of a formation in the right breast craniolateral quadrant, with precise uneven contours, 9.0 cm in size, with infiltrating growth), the tumor formation decreased to US BI-RADS R6, L2. The multidisciplinary council prescribed surgery to the extent of radical mastectomy by Madden on the right and simple mastectomy on the left. The surgery was performed in August 2022. According to a postoperative histological conclusion, the therapeutic pathomorphism was index RCB-2.233, class RCB-II. Conclusion: This article shares the results of systemic and surgical treatment of a man with breast cancer. Considering the clinical picture and anamnesis, literature data, and the clinical protocol, the multidisciplinary group recommended radiation therapy with adjuvant endocrine therapy with tamoxifen for an initial period of five years.
- Open Access
- 31 December 2020
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 58 (4) , 92-95
A good fame on earth – In Memory of Zhanalyk Niyazovich Abdrakhmanov
ОНКОЛОГИЯ и РАДИОЛОГИЯ КАЗАХСТАНА
- 31 December 2020
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 58 (4) , 92-95
Open AccessA good fame on earth – In Memory of Zhanalyk Niyazovich Abdrakhmanov
ОНКОЛОГИЯ и РАДИОЛОГИЯ КАЗАХСТАНА